The lights have dimmed at one of the brightest stars in UK biotech as the artificial intelligence specialist Exscientia plc faces up to the fallout from the sacking of founder and CEO Andrew Hopkins
AI pioneer Exscientia Ltd. has generated the first novel drug candidate in its $1.2bn partnership with Bristol Myers Squibb Company – that being an immune-modulating compound, for which the nine-ye